A detailed history of Bank Of America Corp transactions in Regenxbio Inc. stock. As of the latest transaction made, Bank Of America Corp holds 162,699 shares of RGNX stock, worth $1.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
162,699
Previous 132,748 22.56%
Holding current value
$1.73 Million
Previous $2.38 Million 43.91%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$12.17 - $24.61 $364,503 - $737,094
29,951 Added 22.56%
162,699 $3.43 Million
Q4 2023

Feb 14, 2024

SELL
$12.89 - $20.82 $22,119 - $35,727
-1,716 Reduced 1.28%
132,748 $2.38 Million
Q2 2023

Aug 14, 2023

SELL
$17.23 - $21.71 $1.1 Million - $1.38 Million
-63,786 Reduced 32.17%
134,464 $2.69 Million
Q1 2023

May 12, 2023

BUY
$18.08 - $24.55 $582,790 - $791,344
32,234 Added 19.42%
198,250 $3.75 Million
Q4 2022

Feb 10, 2023

BUY
$20.4 - $24.73 $642,946 - $779,415
31,517 Added 23.43%
166,016 $3.77 Million
Q3 2022

Nov 14, 2022

BUY
$22.29 - $35.04 $2.1 Million - $3.3 Million
94,212 Added 233.85%
134,499 $3.55 Million
Q2 2022

Aug 12, 2022

SELL
$19.35 - $35.04 $2.63 Million - $4.76 Million
-135,907 Reduced 77.13%
40,287 $995,000
Q1 2022

May 16, 2022

BUY
$24.62 - $34.31 $1.31 Million - $1.83 Million
53,240 Added 43.3%
176,194 $5.85 Million
Q4 2021

Feb 08, 2022

BUY
$30.19 - $40.28 $2.27 Million - $3.03 Million
75,246 Added 157.72%
122,954 $4.02 Million
Q3 2021

Nov 15, 2021

SELL
$29.09 - $45.68 $257,242 - $403,948
-8,843 Reduced 15.64%
47,708 $2 Million
Q2 2021

Sep 13, 2021

BUY
$32.46 - $40.48 $1.84 Million - $2.29 Million
56,551 New
56,551 $2.2 Million

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $460M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.